ReviewJournal of inflammation research2026
Bibliometric Insights into Aging and Immune Function in Prostate Cancer: Focus on Chronic Inflammation.
Review in Journal of inflammation research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Intra-arterial delivery of FePt nanoparticles induces ferroptosis and immune infiltration to enhance radiotherapy.Materials today. Bio · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Prostate cancer (PCa) is a leading malignancy among men worldwide, with its progression strongly influenced by aging-associated changes in immune function and chronic inflammation. Chronic inflammation acts as a critical mechanism linking aging and immune dysfunction to tumor initiation, progression, and resistance to therapy. This bibliometric analysis aims to comprehensively evaluate the research landscape on aging, immune function, and chronic inflammation in PCa, identifying key trends, contributors, and emerging strategies for addressing these challenges. Methods: A total of 1,556 publications, spanning January 2015 to October 2025, were retrieved from the Web of Science Core Collection (WoSCC). Bibliometric tools, including VOSviewer, CiteSpace, and Bibliometrix, were employed to analyze publication trends, co-authorship networks, institutional collaborations, and keyword co-occurrences. Special focus was placed on senescence-associated secretory phenotype (SASP) factors, inflammatory biomarkers, and immune dysfunction as aging-related drivers of PCa. Results: Research in this domain has grown significantly over the past two decades, with the United States, China, and Italy emerging as leading contributors. Key themes include the role of SASP factors, oxidative stress, and immune evasion in aging-related PCa progression. Biomarkers such as interleukin-6 (IL-6) and tumor mutational burden (TMB) are increasingly explored for their potential to guide personalized interventions. Emerging therapeutic strategies involve SASP-targeting interventions, immunotherapies like CAR-T cells, and combination approaches to reprogram the immunosuppressive tumor microenvironment. Conclusion: This bibliometric analysis provides a comprehensive overview of research trends at the intersection of aging, immune function, and chronic inflammation in PCa. Rather than establishing mechanistic causality, the findings highlight chronic inflammation as a central and evolving research focus within the field. The results offer a data-driven framework for understanding current research priorities and may inform future mechanistic and translational studies aimed at improving therapeutic strategies for aging-associated PCa.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.